These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 29911959

  • 1. Conversion From Steroid to Everolimus in Maintenance Kidney Transplant Recipients With Posttransplant Diabetes Mellitus.
    Nanmoku K, Kurosawa A, Kubo T, Shinzato T, Shimizu T, Kimura T, Yagisawa T.
    Exp Clin Transplant; 2019 Feb; 17(1):47-51. PubMed ID: 29911959
    [Abstract] [Full Text] [Related]

  • 2. Steroid Withdrawal Using Everolimus in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus.
    Nanmoku K, Shinzato T, Kubo T, Shimizu T, Kimura T, Yagisawa T.
    Transplant Proc; 2018 May; 50(4):1050-1055. PubMed ID: 29631750
    [Abstract] [Full Text] [Related]

  • 3. Effective and Safe Reduction of Conventional Immunosuppressants Using Everolimus in Maintenance Kidney Transplant Recipients.
    Nanmoku K, Kurosawa A, Kubo T, Shinzato T, Shimizu T, Kimura T, Yagisawa T.
    Transplant Proc; 2017 Oct; 49(8):1724-1728. PubMed ID: 28923615
    [Abstract] [Full Text] [Related]

  • 4. Pilot Conversion Study From Mycophenolate Mofetil to Everolimus in Stable ABO-Incompatible Kidney Transplant Recipients: Analysis of 1-Year Follow-Up Data.
    Uchida J, Iwai T, Nishide S, Kabei K, Kuwabara N, Naganuma T, Kumada N, Takemoto Y, Nakatani T.
    Exp Clin Transplant; 2019 Apr; 17(2):190-195. PubMed ID: 30198840
    [Abstract] [Full Text] [Related]

  • 5. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E, Citterio F, Spagnoletti G, Gargiulo A, Delreno F, Romagnoli J, Castagneto M.
    Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
    [Abstract] [Full Text] [Related]

  • 6. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study.
    Nematalla AH, Bakr MA, Gheith OA, Elagroudy AE, Elshahawy el-M, Aghoneim M.
    Exp Clin Transplant; 2007 Dec; 5(2):673-9. PubMed ID: 18194120
    [Abstract] [Full Text] [Related]

  • 7. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B, Athena Study Group.
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [Abstract] [Full Text] [Related]

  • 8. Outcomes of Everolimus Plus Standard-Dose Tacrolimus Immunosuppression in De Novo Kidney Transplant: A Retrospective, Single-Center Study of 225 Transplants.
    Okabe Y, Noguchi H, Sato Y, Mei T, Kaku K, Ueki K, Tsuchimoto A, Nakamura M.
    Exp Clin Transplant; 2022 Mar; 20(4):362-369. PubMed ID: 35475420
    [Abstract] [Full Text] [Related]

  • 9. Steroid avoidance or withdrawal for kidney transplant recipients.
    Pascual J, Zamora J, Galeano C, Royuela A, Quereda C.
    Cochrane Database Syst Rev; 2009 Jan 21; (1):CD005632. PubMed ID: 19160257
    [Abstract] [Full Text] [Related]

  • 10. Conversion of stable kidney transplant recipients from a twice-daily prograf to a once-daily tacrolimus formulation: a short-term study on its effects on glucose metabolism.
    Uchida J, Kuwabara N, Machida Y, Iwai T, Naganuma T, Kumada N, Nakatani T.
    Transplant Proc; 2012 Jan 21; 44(1):128-33. PubMed ID: 22310596
    [Abstract] [Full Text] [Related]

  • 11. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
    Gustafsson F, Andreassen AK, Andersson B, Eiskjær H, Rådegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L, SCHEDULE (Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance) Investigators*.
    Transplantation; 2020 Jan 21; 104(1):154-164. PubMed ID: 30893292
    [Abstract] [Full Text] [Related]

  • 12. Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation.
    Chapman WC, Brown RS, Chavin KD, Sudan D, Koneru B, Junge G, Dong G, Patel D, Teperman L, Fung JJ.
    Transplantation; 2017 Feb 21; 101(2):341-349. PubMed ID: 28121741
    [Abstract] [Full Text] [Related]

  • 13. Safety and metabolic advantages of steroid withdrawal after 6 months posttransplant in de novo kidney transplantation: A 1-year prospective cohort study.
    Bang JB, Oh CK, Kim YS, Kim SH, Yu HC, Kim CD, Ju MK, So BJ, Lee SH, Han SY, Jung CW, Kim JK, Ahn HJ, Lee SH, Jeon JY.
    Immun Inflamm Dis; 2022 Mar 21; 10(3):e576. PubMed ID: 34913271
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK, Huh KH, Ha J, Kim YH, Kim YL, Kim YS.
    Transplantation; 2015 Jan 21; 99(1):180-6. PubMed ID: 24983307
    [Abstract] [Full Text] [Related]

  • 15. Replacement of mycophenolate acid with everolimus in patients who became neutropenic after renal transplant.
    Savvidaki E, Kazakopoulos P, Papachristou E, Karavias D, Zavvos V, Voliotis G, Kalliakmani P, Marangos M, Goumenos DS.
    Exp Clin Transplant; 2014 Feb 21; 12(1):31-6. PubMed ID: 24471721
    [Abstract] [Full Text] [Related]

  • 16. Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain.
    Bilbao I, Salcedo M, Gómez MA, Jimenez C, Castroagudín J, Fabregat J, Almohalla C, Herrero I, Cuervas-Mons V, Otero A, Rubín A, Miras M, Rodrigo J, Serrano T, Crespo G, De la Mata M, Bustamante J, Gonzalez-Dieguez ML, Moreno A, Narvaez I, Guilera M, EVEROLIVER study group.
    Liver Transpl; 2015 Aug 21; 21(8):1056-65. PubMed ID: 25990257
    [Abstract] [Full Text] [Related]

  • 17. Three-year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal.
    Tönshoff B, Tedesco-Silva H, Ettenger R, Christian M, Bjerre A, Dello Strologo L, Marks SD, Pape L, Veldandi U, Lopez P, Cousin M, Pandey P, Meier M.
    Am J Transplant; 2021 Jan 21; 21(1):123-137. PubMed ID: 32406111
    [Abstract] [Full Text] [Related]

  • 18. Outcomes of Early Steroid Withdrawal in Recipients of Deceased-Donor Expanded Criteria Kidney Transplants in the Era of Induction Therapy.
    Hussain SM, Marcus RJ, Ko TY, Nashar K, Thai NL, Sureshkumar KK.
    Exp Clin Transplant; 2016 Jun 21; 14(3):287-93. PubMed ID: 27221720
    [Abstract] [Full Text] [Related]

  • 19. New Recipes With Known Ingredients: Combined Therapy of Everolimus and Low-dose Tacrolimus in De Novo Renal Allograft Recipients.
    Santos T, Santos L, Macário F, Romãozinho C, Alves R, Campos M, Mota A.
    Transplant Proc; 2015 May 21; 47(4):906-10. PubMed ID: 26036483
    [Abstract] [Full Text] [Related]

  • 20. Steroid avoidance or withdrawal for kidney transplant recipients.
    Haller MC, Royuela A, Nagler EV, Pascual J, Webster AC.
    Cochrane Database Syst Rev; 2016 Aug 22; 2016(8):CD005632. PubMed ID: 27546100
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.